Published in Am J Physiol Lung Cell Mol Physiol on October 01, 2001
Acute oxygen-sensing mechanisms. N Engl J Med (2005) 4.80
Cell shrinkage and monovalent cation fluxes: role in apoptosis. Arch Biochem Biophys (2007) 1.56
The role of apoptotic volume decrease and ionic homeostasis in the activation and repression of apoptosis. Pflugers Arch (2004) 1.39
K+ channels in apoptosis. J Membr Biol (2006) 1.29
New mechanisms of pulmonary arterial hypertension: role of Ca²⁺ signaling. Am J Physiol Heart Circ Physiol (2012) 1.24
Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. Br J Pharmacol (2007) 1.04
Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect. Eur J Clin Invest (2013) 1.03
Functional ion channels in human pulmonary artery smooth muscle cells: Voltage-dependent cation channels. Pulm Circ (2011) 0.96
Novel role of KCNQ2/3 channels in regulating neuronal cell viability. Cell Death Differ (2010) 0.89
Mechanisms of oxygen sensing: a key to therapy of pulmonary hypertension and patent ductus arteriosus. Br J Pharmacol (2008) 0.85
High altitude pulmonary hypertension: role of K+ and Ca2+ channels. High Alt Med Biol (2005) 0.83
Chronic cigarette smoke extract treatment selects for apoptotic dysfunction and mitochondrial mutations in minimally transformed oral keratinocytes. Int J Cancer (2010) 0.82
Hypoxia-dependent reactive oxygen species signaling in the pulmonary circulation: focus on ion channels. Antioxid Redox Signal (2015) 0.81
Endothelial and smooth muscle cell ion channels in pulmonary vasoconstriction and vascular remodeling. Compr Physiol (2011) 0.80
Potential therapeutic targets for hypoxia-induced pulmonary artery hypertension. J Transl Med (2014) 0.78
Inhalation of the BK(Ca)-opener NS1619 attenuates right ventricular pressure and improves oxygenation in the rat monocrotaline model of pulmonary hypertension. PLoS One (2014) 0.78
Comparative normal/failing rat myocardium cell membrane chromatographic analysis system for screening specific components that counteract doxorubicin-induced heart failure from Acontium carmichaeli. Anal Chem (2014) 0.77
Fluoxetine protects against big endothelin-1 induced anti-apoptosis by rescuing Kv1.5 channels in human pulmonary arterial smooth muscle cells. Yonsei Med J (2012) 0.76
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension. J Clin Med (2017) 0.75
Pulmonary hypertension-"state of the art" management in 2012. Indian Heart J (2012) 0.75
Anti-proliferation of triple-negative breast cancer cells with physagulide P: ROS/JNK signaling pathway induces apoptosis and autophagic cell death. Oncotarget (2017) 0.75
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med (2000) 4.07
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2001) 3.51
Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence. JAMA (1997) 3.35
Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J (2005) 2.83
Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med (1994) 2.75
Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest (2000) 2.64
Primary pulmonary hypertension. Lancet (1998) 2.47
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J (2006) 2.39
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Upregulated TRP and enhanced capacitative Ca(2+) entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol (2001) 2.35
Primary pulmonary hypertension. Chest (1993) 2.26
Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation (1997) 2.03
Isolation and characterization of the inositol cyclic phosphate products of polyphosphoinositide cleavage by phospholipase C. Physiological effects in permeabilized platelets and Limulus photoreceptor cells. J Biol Chem (1985) 1.98
myo-Inositol polyphosphate may be a messenger for visual excitation in Limulus photoreceptors. Nature (1984) 1.96
Capacitative Ca(2+) entry in agonist-induced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol (2001) 1.94
Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation (1982) 1.92
Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation (1998) 1.80
Oral hydralazine therapy for primary pulmonary hypertension. N Engl J Med (1980) 1.77
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J (2004) 1.73
Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes. Am J Physiol (1993) 1.67
Distinctive clinical features of portopulmonary hypertension. Chest (1997) 1.59
Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet (1998) 1.51
Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest (1997) 1.51
Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature. Medicine (Baltimore) (1986) 1.49
Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes. Am J Physiol Lung Cell Mol Physiol (2001) 1.44
Mortality from primary pulmonary hypertension in the United States, 1979-1996. Chest (2000) 1.44
Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease. Chest (1999) 1.39
Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol Cell Physiol (2000) 1.29
A direct demonstration that inositol-trisphosphate induces an increase in intracellular calcium in Limulus photoreceptors. Biochem Biophys Res Commun (1984) 1.24
NO hyperpolarizes pulmonary artery smooth muscle cells and decreases the intracellular Ca2+ concentration by activating voltage-gated K+ channels. Proc Natl Acad Sci U S A (1996) 1.23
Molecular basis and function of voltage-gated K+ channels in pulmonary arterial smooth muscle cells. Am J Physiol (1998) 1.18
The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis (1989) 1.16
Ionic currents in rat pulmonary and mesenteric arterial myocytes in primary culture and subculture. Am J Physiol (1993) 1.13
Contrasting effects of hypoxia on tension in rat pulmonary and mesenteric arteries. Am J Physiol (1990) 1.11
The renin-angiotensin system and the "lesser circulation". A role in cor pulmonale? Chest (1996) 1.07
Activation of K+ channels induces apoptosis in vascular smooth muscle cells. Am J Physiol Cell Physiol (2001) 1.06
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis (2006) 1.05
The natural history of acute and chronic thromboembolic disease: the search for the missing link. Eur Respir J (2000) 1.05
Ca2+-RhoA signaling pathway required for polyamine-dependent intestinal epithelial cell migration. Am J Physiol Cell Physiol (2001) 1.05
Meat flavor volatiles: a review of the composition, techniques of analysis, and sensory evaluation. Crit Rev Food Sci Nutr (1986) 1.05
Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation (1997) 1.04
Inhibition of K(V) and K(Ca) channels antagonizes NO-induced relaxation in pulmonary artery. Am J Physiol (1997) 1.03
Treatment of primary pulmonary hypertension with nifedipine. A hemodynamic and scintigraphic evaluation. Ann Intern Med (1983) 1.02
Deoxyglucose and reduced glutathione mimic effects of hypoxia on K+ and Ca2+ conductances in pulmonary artery cells. Am J Physiol (1994) 1.00
New and experimental therapies for pulmonary hypertension. Clin Chest Med (2001) 1.00
Role of K(+) channel expression in polyamine-dependent intestinal epithelial cell migration. Am J Physiol Cell Physiol (2000) 1.00
Endogenous testosterone increases L-type Ca2+ channel expression in porcine coronary smooth muscle. Am J Physiol Heart Circ Physiol (2004) 1.00
Bcl-2 decreases voltage-gated K+ channel activity and enhances survival in vascular smooth muscle cells. Am J Physiol Cell Physiol (2001) 0.99
Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol (1997) 0.99
Hypoxic pulmonary vasoconstriction: role of voltage-gated potassium channels. Respir Res (2000) 0.97
Portopulmonary hypertension and the liver transplant candidate. Transplantation (1999) 0.96
Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J (2003) 0.93
Chronic thromboembolic pulmonary hypertension. Clin Chest Med (2001) 0.93
Primary pulmonary hypertension: an unusual case associated with extrahepatic portal hypertension. Hepatology (1983) 0.93
Oxygen-sensitive K(+) channel(s): where and what? Am J Physiol Lung Cell Mol Physiol (2001) 0.89
Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J (2004) 0.89
Nitric oxide inhibits serotonin-induced calcium release in pulmonary artery smooth muscle cells. Am J Physiol (1997) 0.88
c-Jun decreases voltage-gated K(+) channel activity in pulmonary artery smooth muscle cells. Circulation (2001) 0.88
High attenuation mucous plugs in allergic bronchopulmonary aspergillosis: CT appearance. J Comput Assist Tomogr (1992) 0.88
Inhibition of cytochrome P-450 reduces voltage-gated K+ currents in pulmonary arterial myocytes. Am J Physiol (1995) 0.87
Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Exp Physiol (1995) 0.87
Endothelin-1 sensitivity of porcine coronary arteries is reduced by exercise training and is gender dependent. J Appl Physiol (1985) (1999) 0.86
Influence of prostaglandin synthesis inhibitors on pulmonary vasodilatory effects of hydralazine in dogs with hypoxic pulmonary vasoconstriction. J Clin Invest (1981) 0.86
Independence of oxygen consumption and systemic oxygen transport in patients with either stable pulmonary hypertension or refractory left ventricular failure. Am Rev Respir Dis (1983) 0.86
Current treatment strategies for pulmonary arterial hypertension. J Intern Med (2005) 0.86
"High probability" perfusion lung scans in pulmonary venoocclusive disease. Am J Respir Crit Care Med (2000) 0.86
Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation (1998) 0.86
Pulmonary vasoconstrictor effects of prostacyclin in rats: potential role of thromboxane receptors. J Appl Physiol (1985) (1996) 0.85
Anion exchange chromatographic separation of inositol phosphates and their quantification by gas chromatography. Anal Biochem (1989) 0.85
A mitochondrial uncoupler increases KCa currents but decreases KV currents in pulmonary artery myocytes. Am J Physiol (1996) 0.85
Survival and differentiation of human embryonic stem cell-derived neural precursors grafted spinally in spinal ischemia-injured rats or in naive immunosuppressed minipigs: a qualitative and quantitative study. Cell Transplant (2012) 0.84
Increased levels of prostaglandin D(2) suggest macrophage activation in patients with primary pulmonary hypertension. Chest (2001) 0.84
Action of fenfluramine on voltage-gated K+ channels in human pulmonary-artery smooth-muscle cells. Lancet (1998) 0.83
Hemodynamics at rest and during exercise after oral hydralazine in patients with cor pulmonale. Am J Cardiol (1981) 0.82
A comparison of the acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. Am Heart J (1985) 0.82
Anorexic effect of K+ channel blockade in mesenteric arterial smooth muscle and intestinal epithelial cells. J Appl Physiol (1985) (2001) 0.82
Pulmonary vascular structural and functional changes in papain-induced emphysema in dogs. Am Rev Respir Dis (1987) 0.81
The effects of oral hydralazine on right ventricular end-diastolic pressure in patients with right ventricular failure. Circulation (1982) 0.81
Prostacyclin and PGE1 treatment of pulmonary hypertension. Am Rev Respir Dis (1987) 0.81
Reversible pulmonary hypertension associated with anorexigen use. Am J Med (1991) 0.81
Postpartum reactions: some unrecognized variations. Am J Psychiatry (1974) 0.81